·¢²¼Ê±¼ä£º2014-10-22 À´Ô´£ºÈË´ó¾­¼ÃÂÛ̳

Õª Òª ÔÚ¹ýÈ¥10ÄêÖжùͯÎÞ·´Ó¦»ò¸´·¢ÐÔALLµÄÖÎÁÆÒ»Ö±´¦ÓÚÒ»¸öƽ̨ÆÚ£¬´ó²¿·Ö¸´·¢µÄ¶ùͯԤºóÈÔ²»¼Ñ£¬Òò¶øÎÒÃÇÈÔÐèÒª¼ÌÐø¿ª·¢Ð¶øÓÐЧµÄÖÎÁÆÒ©Îï¡£ÂÈ·¨À­±õΪÕâЩ»¼¶ù´øÀ´ÁËÏ£Íû£¬Í¬Ê±ÂÈ·¨À­±õÔÚ¸´·¢»òµÖ¿¹ÐÔ¼±ÐÔËèϸ°ûÐÔ°×Ѫ²¡»¼¶ùÖÐÒ²ÏÔʾϣÍû¡£ ±¾ÊµÑéÓñ½¼×õ£»¯ÂÈ·¨À­±õÖмäÌåºÍ¼×´¼ºÏ³ÉÂÈ·¨À­±õ£¬¶Ô·´Ó¦Ìõ¼þ½øÐÐÓÅ»¯£¬Ì½Ë÷²»Í¬Î¶ȼ°´ß»¯¼ÁͶÈëÁ¿´óС¶Ô²úÆ·ÊÕÂÊ¡¢´¿¶ÈÒÔ¼°·´Ó¦Ê±¼äµÄÓ°Ïì¡£¾­¹ý¶à×éʵÑéÂÛÖ¤£¬×ܽá³ö×îÊʵķ´Ó¦Ìõ¼þ¼°ÓÅ»¯µÄʵÑé²½Ö裬ͨ¹ý½á¹¹·ÖÎö£¬È·ÈϲúÎïΪÂÈ·¨À­±õ¡£ ¹Ø¼ü´Ê ÂÈ·¨À­±õ ¼×´¼ ¾ø¶ÔÎÞË®¼×´¼ ¼ì²â Abstract In the past 10 year¡¯s children in non-response or relapse of ALL treatment has been in a period of a platform, most of the children recurrence prognosis is still poor, so we still need to continue to develop new and effective treatments. Clofarabine for these children has brought hope and clofarabine in the resistance or recurrence of acute myeloid leukemia patients in the hope that the show also. Benzoyl use of clofarabine intermediates and methanol synthesis clofarabine satisfied that the conditions to optimize and explore different temperature catalyst volume and size of the yield, purity and the reaction time of impact. After experimental demonstration group, summed up the optimum conditions for the release should be optimized and the experimental steps. Compared with the past, product quality, yield and reaction time have a significant improvement . Key words clofarabine methanol sodium anhydrous methanol detection Ä¿ ¼ ÎÄÏ××ÛÊö 1.1ÂÈ·¨À­±õµÄÑз¢±³¾°¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­1 1.2ÂÈ·¨À­±õµÄ¹úÄÚÍâÉú²ú×´¿ö¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­1 1.3ÂÈ·¨À­±õµÄÀí»¯ÐÔÖÊ¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­1 1.4ÂÈ·¨À­±õµÄ×÷ÓûúÖÆ¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­2 1.5ÂÈ·¨À­±õµÄҩЧѧ¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­3 1.6ÂÈ·¨À­±õµÄÒ©¶¯Ñ§¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­4 1.7ÂÈ·¨À­±õµÄÁÙ´²Ñо¿¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­4 1.7.1µ¥Óá­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­5 1.7.2ÁªºÏÖÎÁÆ¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­6 1.8ÂÈ·¨À­±õÓëÆäËûÒ©ÎïµÄÏ໥×÷Óà ¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­6 1.9ÂÈ·¨À­±õµÄ²»Á¼·´Ó¦ ¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­6 1.10ÂÈ·¨À­±õµÄ¿ª·¢Ç°¾° ¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­7 ʵÑ鲿·Ö 2.1È·¶¨Ä¿±ê»¯Îï¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­8 2.2Éè¼ÆºÏ³É·Ïß¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­9 2.3ÂÈ·¨À­±õµÄÖƱ¸¹¤ÒÕÑо¿¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­12 2.3.1»¯Ñ§·´Ó¦Ê½¼°·´Ó³Ìõ¼þ¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­12 2.3.2ʵÑéÒÇÆ÷¡¢ÊÔ¼Á¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­12 2.3.3ºÏ³É¹¤ÒÕµÄÑо¿¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­13 2.4ζȶÔÖƱ¸¹¤ÒÕµÄÓ°Ïì¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­14 2.5´ß»¯¼ÁͶÈëÁ¿¶ÔÖƱ¸¹¤ÒÕµÄÓ°Ïì¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­15 2.6ÂÈ·¨À­±õµÄ´¿»¯¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­17 ²úÆ··ÖÎö 3.1ºìÍâÎüÊÕ¹âÆס­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­18 3.2×ÏÍâÎüÊÕ¹âÆס­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­20 3.3ÖÊÆס­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­21 3.4×ۺϷÖÎö¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­22 ½áÂÛ 4.1ºÏ³É·Ïß¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­23 4.2ºÏ³É²½Öè¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­23 ÖÂл ¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­24 ²Î¿¼ÎÄÏס­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­¡­25